|
TRAC Portfolio - Calimmune, Inc. |
 |
|
|
|
|
Calimmune, Inc. (Tucson, Arizona) is developing a stem cell HIV/AIDS therapy that blocks the expression of the CCR5 co-receptor on T lymphocytes. After Dr. David Baltimore (President Emeritus of Caltech/Nobel Laureate) and Dr. Irvin Chen (Director of the UCLA AIDS Institute) established proof-of-concept and animal safety/efficacy data, Calimmune is now taking this innovative therapy to the clinic. The Company is currently progressing through pre-IND tests.
|
Date:
May 8, 2008 |
Stage:
Seed |
| |
| |
|
|
|
| |
|
|
|
| |
